Medmix Valuation Multiples

Discover revenue and EBITDA valuation multiples for Medmix and similar public comparables like LPKF Laser & Electronics, Revenio Group, Anbio Biotechnology, Columbus McKinnon and more.

Medmix Overview

About Medmix

Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery, and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of its revenue is from the Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways, and aerospace), electronics assembly, infrastructure, and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas, and Asia-Pacific.


Founded

2021

HQ

Switzerland

Employees

2.7K

Financials (LTM)

Revenue: $565M
EBITDA: $113M

EV

$717M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Medmix Financials

Medmix reported last 12-month revenue of $565M and EBITDA of $113M.

In the same LTM period, Medmix generated $205M in gross profit, $113M in EBITDA, and $19M in net income.

Revenue (LTM)


Medmix P&L

In the most recent fiscal year, Medmix reported revenue of $579M and EBITDA of $112M.

Medmix is profitable as of last fiscal year, with gross margin of 35%, EBITDA margin of 19%, and net margin of 3%.

See analyst estimates for Medmix
LTMLast FY202320242025202620272028
Revenue$565M$579M$603M$599M$555M
Gross Profit$205M$201M$195M$198M$201M
Gross Margin36%35%32%33%36%
EBITDA$113M$112M$88M$83M$93M
EBITDA Margin20%19%15%14%17%
EBIT Margin7%6%3%4%6%
Net Profit$19M$20M$372K($9M)$8M
Net Margin3%3%0%(2%)1%
Net Debt-$218M---

Financial data powered by Morningstar, Inc.

Medmix Stock Performance

Medmix has current market cap of $420M, and enterprise value of $717M.

Market Cap Evolution


Medmix's stock price is $10.32.

Medmix share price increased by 5.5% in the last 30 days, and decreased by 32.3% in the last year.

Medmix has an EPS (earnings per share) of $0.48.

See more trading valuation data for Medmix
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$717M$420M0.1%5.5%-2.0%-32.3%$0.48

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Medmix Valuation Multiples

Medmix trades at 1.3x EV/Revenue multiple, and 6.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Medmix

EV / Revenue (LTM)


Medmix Financial Valuation Multiples

As of July 19, 2026, Medmix has market cap of $420M and EV of $717M.

Medmix has a P/E ratio of 22.6x.

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.2x1.2x1.2x1.3x
EV/EBITDA6.3x6.4x8.1x8.6x7.7x
EV/EBIT17.9x19.4x40.7x32.0x20.8x
EV/Gross Profit3.5x3.6x3.7x3.6x3.6x
P/E22.6x21.4xn/m(45.8x)52.9x
EV/FCF28.0x21.7x180.8x15.2x21.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Medmix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Medmix Margins & Growth Rates

Medmix decreased revenue by 4% but EBITDA grew by 2% in the last fiscal year.

In the most recent fiscal year, Medmix reported gross margin of 35%, EBITDA margin of 19%, and net margin of 3%.

See estimated margins and future growth rates for Medmix

Medmix Margins

Last FY202420252026202720282029
Gross Margin35%33%36%36%
EBITDA Margin19%14%17%21%
EBIT Margin6%4%6%8%
Net Margin3%(2%)1%3%
FCF Margin6%8%6%5%

Medmix Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(4%)(1%)(7%)(0%)
Gross Profit Growth0%1%1%0%
EBITDA Growth2%(6%)12%23%
EBIT Growth16%27%54%24%
Net Profit Growth(10%)(2567%)(186%)124%
FCF Growth(20%)1091%(30%)(20%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Medmix Operational KPIs

Medmix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Medmix's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medmix's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Medmix
LTMLast FY202320242025202620272028
Rule of 4021%20%---
Bessemer Rule of X23%20%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue-25%24%24%26%
R&D Expenses to Revenue5%5%5%5%4%
Opex to Revenue-29%29%29%30%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
LPKF Laser & Electronics3.1x3.2x563.2x194.8x
Revenio Group3.1x2.6x10.9x10.6x
Anbio Biotechnology46.8x-70.2x-
Columbus McKinnon3.0x2.5x19.8x14.7x
Imricor Medical Systems1349.7x196.0x(18.3x)(17.1x)
Carvolix95.4x307.2x(32.9x)(17.6x)
Medistim5.6x5.3x16.7x17.4x
Elmet Group2.4x2.2x20.6x19.0x

This data is available for Pro users. Sign up to see all Medmix competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Medmix

When was Medmix founded?Medmix was founded in 2021.
Where is Medmix headquartered?Medmix is headquartered in Switzerland.
How many employees does Medmix have?As of today, Medmix has over 2K employees.
Is Medmix publicly listed?Yes, Medmix is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Medmix?Medmix trades under MEDX ticker.
When did Medmix go public?Medmix went public in 2021.
Who are competitors of Medmix?Medmix main competitors include LPKF Laser & Electronics, Revenio Group, Anbio Biotechnology, Columbus McKinnon, Imricor Medical Systems, Carvolix, Medistim, Elmet Group, Kamada, L.B. Foster.
What is the current market cap of Medmix?Medmix's current market cap is $420M.
What is the current revenue of Medmix?Medmix's last 12 months revenue is $565M.
What is the current revenue growth of Medmix?Medmix revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of Medmix?Current revenue multiple of Medmix is 1.3x.
What is the current EBITDA of Medmix?Medmix's last 12 months EBITDA is $113M.
What is Medmix's EBITDA margin?Medmix's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Medmix?Current EBITDA multiple of Medmix is 6.3x.
What is the current FCF of Medmix?Medmix's last 12 months FCF is $26M.
What is Medmix's FCF margin?Medmix's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Medmix?Current FCF multiple of Medmix is 28.0x.
How many companies Medmix has acquired to date?Medmix hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Medmix has invested to date?Medmix hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Medmix

Lists including Medmix

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial